Table 1. Characteristics of the study population (n=82).
| Characteristic | n | % |
|---|---|---|
| Gender | ||
| Female | 41 | 50.0 |
| Male | 41 | 50.0 |
| ASA | ||
| 1 | 1 | 1.2 |
| 2 | 45 | 54.9 |
| 3 | 33 | 40.2 |
| 4 | 3 | 3.7 |
| ECOG | ||
| 0 | 2 | 2.4 |
| 1 | 24 | 29.3 |
| 2 | 34 | 41.5 |
| 3 | 17 | 20.7 |
| 4 | 5 | 6.1 |
| Primary site | ||
| Lung | 82 | 100.0 |
| Procedure | ||
| Pleurodesis | 35 | 42.7 |
| VAT/pleuroscopy | 11 | 13.4 |
| Thoracocentesis | 30 | 36.6 |
| Indwelling pleural catheter | 6 | 7.3 |
| Pleural histology/cytology | ||
| Negative | 15 | 18.1 |
| Positive | 63 | 65.9 |
| Recurrence | ||
| No | 67 | 81.7 |
| Yes | 15 | 18.3 |
| Chemotherapy line | ||
| No treatment—first line palliative | 56 | 68.3 |
| Chemotherapy palliative | 13 | 15.9 |
| Chemotherapy palliative > first line | 13 | 15.9 |
| Metastasis | ||
| 0 | 34 | 44.2 |
| 1 | 6 | 20.8 |
| 2 | 17 | 21.2 |
| ≥3 | 10 | 13 |
Metastasis: the number of metastatic sites was also evaluated, which was defined as presence of any numbers of metastasis at each organ. ASA, American Society of Anesthesiologists; ECOG: Eastern Cooperative Oncology Group performance status score; VAT, video-assisted thoracoscopy.